Humanigen Inc

76 articles about Humanigen Inc

• Humanigen Reports Second Quarter 2022 Financial Results

  8/12/2022

  Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.

• 

  NIH Study Unable to Confirm Benefit of Humanigen’s Lenzilumab in COVID-19

  7/13/2022

  An NIH-sponsored trial assessing a combination of Humanigen's lenzilumab and Gilead Sciences’ remdesivir in hospitalized COVID-19 patients failed to achieve the primary endpoint.

• Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B

  7/13/2022

  Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases’ (NIAID) ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.

• Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein

  7/6/2022

  Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein.

• NIH/NIAID Locks ACTIV-5/BET-B Database

  6/30/2022

  Humanigen, Inc. confirms that notice was received from the National Institute of Allergy and Infectious Diseases that they have completed database lock for the Big Effect Trial of lenzilumab being conducted as part of the National Institutes of Health public-private partnership Accelerating COVID-19 Therapeutic Interventions and Vaccines.

• Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom

  6/16/2022

  Humanigen, Inc. announced it entered into an agreement with PCI Pharma Services, a leading integrated global contract development manufacturing organization, to provide importation, release and commercialization services in the United Kingdom for lenzilumab.

• Humanigen Announces Participation and Presentation at Multiple Conferences in June

  6/3/2022

  Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that representatives will present and participate at multiple investors conferences in June 2022.

• Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference

  5/24/2022

  Humanigen, Inc., a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced that Cameron Durrant, Chairman & CEO, will give a corporate presentation at 11:00am EDT at the H.C. Wainwright Global Investment Conference taking place in Miami, FL, May 23-26, 2022.

• Humanigen Reports First Quarter 2022 Financial Results

  5/5/2022

  Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

• Humanigen Announces Participation and Presentation at Multiple Conferences in May

  5/4/2022

  Humanigen, Inc. announced today that management will present and participate at multiple investors conferences in May 2022.

• GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia

  4/20/2022

  Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today a peer-reviewed publication in Leukemia, a leading oncology and hematology journal, entitled “GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity.”

• Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS

  4/19/2022

  Humanigen, Inc. announced a peer-reviewed publication in ClinicoEconomics and Outcomes Research outlining the potential clinical and health economic benefits of lenzilumab, if authorized or approved for use in the United Kingdom.

• Humanigen Reports Year-End 2021 Financial Results

  2/28/2022

  Humanigen, Inc. today reported financial results for the year ended December 31, 2021, and announced corporate objectives for 2022.

• Humanigen to Present and Participate at Multiple Investor Events in March 2022

  2/25/2022

  Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that management will present and participate at several events in March with investors, analysts, bankers and potential partners.

• Humanigen to Present at BIO CEO & Investor Conference

  2/11/2022

  Humanigen, Inc. announced that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

• Humanigen Launches Managed Access Program for Lenzilumab

  2/10/2022

  Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program.

• Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France

  2/9/2022

  Humanigen, Inc. and Cenexi announced a collaboration aimed at making Cenexi a preferred supplier of lenzilumab in France and the European Union.

• Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab

  1/18/2022

  Humanigen, Inc. announced a peer-reviewed publication in the Journal of Medical Economics citing the clinical and associated health economic benefits of lenzilumab.

• Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

  1/10/2022

  Humanigen, Inc. outlined the next steps for the development of its lead candidate, lenzilumab, in the prevention of CAR-T therapy related toxicities including ICANS and CRS in patients with relapsed or refractory Non-Hodgkin lymphoma.

• Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved

  1/5/2022

  Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’, announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study has been achieved.